According to our (Global Info Research) latest study, the global Drugs for PrEP market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Drugs for Pre-Exposure Prophylaxis (PrEP) are antiretroviral medications used to prevent HIV infection in individuals at high risk of exposure. These drugs work by blocking the replication of HIV in the body if exposure occurs, significantly reducing the risk of infection. Taken daily, PrEP can lower HIV transmission risk by up to 99%. PrEP is recommended for individuals at high risk, such as men who have sex with men (MSM), people with HIV-positive partners, or those who engage in high-risk sexual activities or injectable drug use. In addition to oral medications, long-acting injectable forms like cabotegravir are being developed and used to enhance adherence and accessibility.
This report is a detailed and comprehensive analysis for global Drugs for PrEP market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drugs for PrEP market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for PrEP market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for PrEP market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for PrEP market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for PrEP
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for PrEP market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Drugs for PrEP market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Oral Drugs
Injections
Market segment by Application
Hospital and Clinic
Pharmacy
Other
Major players covered
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for PrEP product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for PrEP, with price, sales quantity, revenue, and global market share of Drugs for PrEP from 2021 to 2026.
Chapter 3, the Drugs for PrEP competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for PrEP breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for PrEP market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for PrEP.
Chapter 14 and 15, to describe Drugs for PrEP sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Drugs for PrEP. Industry analysis & Market Report on Drugs for PrEP is a syndicated market report, published as Global Drugs for PrEP Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Drugs for PrEP market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.